# Hepatitis C Virus Infection Induces Autoimmune Hypothyroidism with Potential Profound Metabolic Implications: A Cross-Sectional Study in a High-Prevalence Region

**Authors:** Xiaoli Zhong, Waseem Abbas, Farman Ullah, Rafi Ullah

PMC · DOI: 10.3390/metabo16020104 · 2026-01-31

## TL;DR

This study finds that Hepatitis C Virus infection is strongly linked to autoimmune thyroid disease, which could lead to serious metabolic issues.

## Contribution

The study identifies a strong association between HCV infection and autoimmune hypothyroidism, suggesting potential metabolic consequences.

## Key findings

- 41% of HCV patients had thyroid dysfunction compared to 12% of controls.
- Anti-TPO antibodies were 38% positive in HCV patients versus 8% in controls.
- Thyroid dysfunction was more common in older HCV patients and those with higher viral loads.

## Abstract

Background: Thyroid hormones regulate energy homeostasis, lipid/glucose metabolism, and protein turnover. Chronic Hepatitis C Virus (HCV) infection is highly associated with autoimmune hypothyroidism, which may have profound metabolic implications. This study evaluates thyroid dysfunction and anti-thyroid peroxidase (anti-TPO) autoimmunity in HCV patients and explores its potential metabolic implications in a high-prevalence region. Methods: In this comparative cross-sectional study adhering to STROBE guidelines, we enrolled 100 PCR-confirmed chronic HCV patients and 100 age/gender-matched controls from District Peshawar, Pakistan. Serum TSH, fT3, fT4, and anti-TPO antibodies were quantified. Multivariable logistic regression, adjusted for age, gender, and viral load, was used to compute adjusted odds ratios (aOR) with 95% confidence intervals (CI). Results: Thyroid dysfunction affected 41% of HCV patients vs. 12% of controls (aOR 5.2, 95% CI 2.8–9.6, p < 0.001), predominantly hypothyroidism (29% overall; 18% overt, 11% subclinical). Anti-TPO positivity was 38% in HCV vs. 8% in controls (aOR 6.7, 95% CI 3.1–14.5, p < 0.001). Anti-TPO titers correlated positively with TSH (r = +0.62, p < 0.001) and inversely with fT3/fT4. Subgroup analysis showed higher dysfunction in patients aged ≥40 years (52% vs. 28%, p = 0.012) and viral load ≥ 106 IU/mL (48% vs. 32%, p = 0.041). We hypothesize that these findings may have significant metabolic implications, including impaired mitochondrial β-oxidation and insulin resistance. Conclusions: HCV infection is strongly associated with autoimmune hypothyroidism, which may amplify cardiometabolic risk. The paper has not explicitly identified metabolic parameters, including lipid profiles, indices of insulin resistance, and metabolomic signatures, and, therefore, any metabolic inferences are speculative and based on established thyroid and HCV pathophysiology. Routine thyroid screening pre- and post-DAA therapy is recommended, alongside metabolomic profiling to validate these proposed metabolic pathways.

## Full-text entities

- **Genes:** UCP3 (uncoupling protein 3) [NCBI Gene 7352] {aka SLC25A9}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, CTLA4 (cytotoxic T-lymphocyte associated protein 4) [NCBI Gene 1493] {aka ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, SLC2A4 (solute carrier family 2 member 4) [NCBI Gene 6517] {aka GLUT4}, TPO (thyroid peroxidase) [NCBI Gene 7173] {aka MSA, TDH2A, TPX}, LDLR (low density lipoprotein receptor) [NCBI Gene 3949] {aka LDLCQ2}, IRS1 (insulin receptor substrate 1) [NCBI Gene 3667] {aka HIRS-1}, SLC5A5 (solute carrier family 5 member 5) [NCBI Gene 6528] {aka NIS, TDH1}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, CYP7A1 (cytochrome P450 family 7 subfamily A member 1) [NCBI Gene 1581] {aka CP7A, CYP7, CYPVII}, CPT1A (carnitine palmitoyltransferase 1A) [NCBI Gene 1374] {aka CPT I, CPT1, CPT1-L, CPTI-L, L-CPT1}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, HLA-DRB4 (major histocompatibility complex, class II, DR beta 4) [NCBI Gene 3126] {aka DR4, DRB4, HLA-DR4B, HLA-DRB, HLA-DRB4*}, SPP1 (secreted phosphoprotein 1) [NCBI Gene 6696] {aka BNSP, BSPI, ETA-1, OPN}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, ERVK-6 (endogenous retrovirus group K member 6, envelope) [NCBI Gene 64006] {aka ERVK6, HERV-K(C7), HERV-K108, K-Rev, c-orf, cORF}
- **Diseases:** Autoimmune Thyroiditis (MESH:D013967), Thyroid dysfunction (MESH:D013959), hypercholesterolemia (MESH:D006937), lymphoproliferative conditions (MESH:D008232), thyroid hormone deficiency (MESH:D018382), chronic (MESH:D002908), immune dysregulation (OMIM:614878), Hypothyroid (MESH:D007037), deficiency (MESH:D007153), viral (MESH:D014777), Autoimmune Hypothyroidism (MESH:C562768), HCV (MESH:D006526), rheumatoid arthritis (MESH:D001172), weight dysregulation (MESH:D015431), insulin resistance (MESH:D007333), iodine deficiency (MESH:D003409), hepatotropic infection (MESH:D007239), cardiovascular disease (MESH:D002318), autoimmune endocrine diseases (MESH:D004700), chronic viral hepatitis (MESH:D006525), Euthyroid (MESH:D005067), fatigue (MESH:D005221), Hyperthyroid (MESH:D006980), Hepatic steatosis (MESH:D005234), autoimmune (MESH:D001327), Wilson's disease (MESH:D006527), chronic lymphocytic thyroiditis (MESH:D050031), SLE (MESH:D008180), metabolic dysregulation (MESH:D021081), metabolic disease (MESH:D008659), Thyroid Status (MESH:D013966), dyslipidemia (MESH:D050171), mitochondrial dysfunction (MESH:D028361), injury to (MESH:D014947), liver disease (MESH:D008107), inflammation (MESH:D007249), liver fibrosis (MESH:D008103), autoimmune disruptions (MESH:D019958), chronic kidney disease (MESH:D051436), Chronic HCV infection (MESH:D019698), thyroid failure (MESH:D051437), cryoglobulinemia (MESH:D003449), NAFLD (MESH:D065626), Diabetes mellitus (MESH:D003920), malignancy (MESH:D009369)
- **Chemicals:** lipid (MESH:D008055), iodine (MESH:D007455), amiodarone (MESH:D000638), ATP (MESH:D000255), glucose (MESH:D005947), ROS (MESH:D017382), T3 (MESH:D014284), carnitine (MESH:D002331), DAA (-), T4 (MESH:D013974), bile acid (MESH:D001647), acyl-carnitines (MESH:C116917), selenium (MESH:D012643), fatty acids (MESH:D005227), lithium (MESH:D008094), glycogen (MESH:D006003), cholesterol (MESH:D002784), iodide (MESH:D007454), BCAAs (MESH:D000597), aromatic amino acids (MESH:D024322), triglyceride (MESH:D014280)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12942145/full.md

---
Source: https://tomesphere.com/paper/PMC12942145